Tempus AI is projected to report Q2 2026 revenue of $381.6 million and an EPS loss of $0.41, with its current share price of $43.96 trading significantly below the $70.00 consensus analyst price target. The primary focus for investors this quarter is the integration of the recently announced $1.5 billion acquisition of Personalis and its expansion into the molecular residual disease (MRD) testing space.
Analysts are also closely monitoring the performance of the core Diagnostics segment, which has seen accelerating clinical volumes in oncology and hereditary sequencing. Management's progress toward achieving sustainable positive adjusted EBITDA remains a critical theme as the company scales its AI-driven foundation models for precision medicine.